Suppr超能文献

慢性大麻素暴露可减少成年大鼠中苯环利定诱导的精神分裂症样阳性症状。

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

机构信息

CNR Neuroscience Institute, National Research Council, Monserrato (Cagliari), Italy.

出版信息

Psychopharmacology (Berl). 2013 Feb;225(3):531-42. doi: 10.1007/s00213-012-2839-1. Epub 2012 Aug 19.

Abstract

RATIONALE

Chronic cannabis use can induce psychotic states that resemble schizophrenia. Yet, schizophrenic patients often smoke cannabis as a form of self-medication to counter the aversive symptoms of schizophrenia. We recently demonstrated an ameliorating effect of cannabinoid self-administration (SA) on negative and cognitive schizophrenia-like symptoms induced experimentally by the non-competitive N-methyl-D-aspartate receptor antagonist phencyclidine (PCP). Whether cannabinoid SA alleviates or exacerbates schizophrenia-like positive symptoms is still unclear.

OBJECTIVES

This follow-up study aimed to evaluate the effect of self-administered cannabinoid on PCP-induced schizotypic positive symptoms in adult rats.

METHODS

Male rats were trained to self-administer either the cannabinoid CB1 receptor agonist WIN 55,212-2 (WIN; 12.5 μg/kg/infusion) or its vehicle (Veh) intravenously. The effects of acute and chronic intermittent intraperitoneal administration of PCP (2.5 mg/kg) on motor parameters were then tested in Veh-SA and WIN-SA.

RESULTS

Cannabinoid SA significantly attenuated the psychotomimetic effects of PCP exposure observed in control rats. Following acute PCP administration, WIN-SA animals displayed more frequent rearing and lower anxiety-like profile than Veh-SA rats. WIN-SA rats also exhibited lower behavioural sensitisation to chronic PCP treatment as demonstrated by reduced hyperlocomotion in response to an acute PCP challenge. In addition, parallel experiments performed in experimenter-administered rats that received WIN at comparable SA doses confirmed the ameliorating effects of cannabinoid exposure on PCP-induced schizotypic behaviours, indicating that motivational effects were not responsible for the ameliorative effects of cannabinoids.

CONCLUSIONS

Our results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state.

摘要

背景

慢性大麻使用会导致类似精神分裂症的精神病状态。然而,精神分裂症患者经常吸食大麻作为一种自我药物治疗的形式,以对抗精神分裂症的厌恶症状。我们最近证明了大麻素自我给药(SA)对非竞争性 N-甲基-D-天冬氨酸受体拮抗剂苯环利定(PCP)实验诱导的阴性和认知类精神分裂样症状有改善作用。大麻素 SA 是否减轻或加重类精神分裂症阳性症状仍不清楚。

目的

本后续研究旨在评估自我给予大麻素对成年大鼠中 PCP 诱导的类精神分裂症阳性症状的影响。

方法

雄性大鼠接受训练,以静脉内自我给予大麻素 CB1 受体激动剂 WIN 55,212-2(WIN;12.5μg/kg/剂量)或其载体(Veh)。然后在 Veh-SA 和 WIN-SA 大鼠中测试急性和慢性间歇性腹腔内给予 PCP(2.5mg/kg)对运动参数的影响。

结果

大麻素 SA 显著减轻了对照大鼠中观察到的 PCP 暴露的精神病样效应。在急性 PCP 给药后,WIN-SA 动物比 Veh-SA 大鼠表现出更频繁的竖起和更低的焦虑样特征。WIN-SA 大鼠还表现出对慢性 PCP 治疗的行为敏化作用降低,表现为对急性 PCP 挑战的过度运动减少。此外,在接受可比 SA 剂量 WIN 的实验者给予大鼠中进行的平行实验证实了大麻素暴露对 PCP 诱导的类精神分裂症行为的改善作用,表明动机作用不是大麻素改善作用的原因。

结论

我们的结果表明,大麻可能对成年动物的阳性类精神分裂症症状(如多动和焦虑状态)产生保护作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验